Increased Levels of IGF-1 and Beta2-microglobulin in Epithelial Lining Fluid of Preterm Newborns Developing Chronic Lung Disease. Effects of RhG-CSF
Overview
Pathology
Pharmacology
Authors
Affiliations
Unlabelled: Insulin-like growth factor-1 (IGF-1) is involved in regulating the Th-1/Th-2 balance, favoring the development of the Th-2 compartment which enhances fibrosis, one of the main characteristics of Chronic Lung Disease (CLD) in premature newborns. Limited data is available concerning a possible association between early epithelial lining fluid (ELF) concentrations of IGF-1 (total and free forms), IGF-binding protein-3 (IGFBP-3), beta2-microglobulin and subsequent development of CLD in preterm neonates. If neutropenic, preterm neonates are frequently treated with recombinant human granulocyte colony stimulating factor (rhG-CSF). The objective of the study was to correlate ELF concentrations of IGF-1 and beta2 microglobulin during the first week of life both in non-neutropenic and in rhGCSF-treated neutropenic preterm neonates, with subsequent development in CLD. Thirty preterm neonates with Respiratory Distress Syndrome (6 with neutropenia) were studied. Eleven out of 24 non-neutropenic preterm infants (46%) and all of the six neutropenic subjects (100%) developed CLD. With the exception of first day values, there was a clear similarity in the behaviors of assayed molecules between non-neutropenic and neutropenic patients developing CLD. Non-neutropenic patients without CLD showed significantly lower values of free IGF-1 and beta2M both on days 1 and 3. Total IGF-I and cell counts were different only on the 3rd day.
Conclusions: 1) the mechanisms leading to CLD might be mediated by high levels of IGF-family molecules soon after birth 2) beta2M could be a marker of increased bronchoalveolar lavage fluid cellularity with potential inflammatory properties 3) G-CSF treatment induces an increased synthesis of IGF-1 molecules by cells recruited in the lung, with possible enhancement of the fibrogenic mechanisms.
Ling X, Huang P, Chen H, Hsueh Y, Lee C, Lien R Front Pediatr. 2024; 11:1195904.
PMID: 38259597 PMC: 10800500. DOI: 10.3389/fped.2023.1195904.
Gorgisen G, Aydin M, Mboma O, Gokyildirim M, Chao C Int J Mol Sci. 2022; 23(17).
PMID: 36077511 PMC: 9456457. DOI: 10.3390/ijms231710113.
Insulin-like growth factor-1: A potential target for bronchopulmonary dysplasia treatment (Review).
Zhang S, Luan X, Li H, Jin Z Exp Ther Med. 2022; 23(3):191.
PMID: 35126694 PMC: 8794548. DOI: 10.3892/etm.2022.11114.
Insulin-Like Growth Factor-1 Signaling in Lung Development and Inflammatory Lung Diseases.
Wang Z, Li W, Guo Q, Wang Y, Ma L, Zhang X Biomed Res Int. 2018; 2018:6057589.
PMID: 30018981 PMC: 6029485. DOI: 10.1155/2018/6057589.
Mutlu F, Sarici S Int J Ophthalmol. 2013; 6(2):228-36.
PMID: 23641347 PMC: 3633766. DOI: 10.3980/j.issn.2222-3959.2013.02.23.